Morgan Stanley Equillium, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.83 - $2.26 $4 - $13	6 Added 200.0%	9 $0
Q3 2022 Nov 14, 2022	SELL	$1.93 - $3.14 $119 - $194	-62 Reduced 95.38%	3 $0
Q2 2022 Oct 27, 2022	SELL	$1.69 - $3.26 $3,668 - $7,077	-2,171 Reduced 97.09%	65 $0
Q2 2022 Aug 15, 2022	SELL	$1.69 - $3.26 $3,668 - $7,077	-2,171 Reduced 97.09%	65 $0
Q1 2022 Oct 27, 2022	BUY	$2.99 - $4.19 $6,491 - $9,096	2,171 Added 3340.0%	2,236 $7,000
Q1 2022 May 13, 2022	SELL	$2.99 - $4.19 $873 - $1,223	-292 Reduced 11.55%	2,236 $7,000
Q4 2021 Feb 14, 2022	BUY	$3.77 - $6.99 $8,682 - $16,097	2,303 Added 1023.56%	2,528 $9,000
Q3 2021 Nov 15, 2021	BUY	$4.84 - $6.91 $1,089 - $1,554	225 New	225 $1,000

11.5M

38.1K

Ticker EQ
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,352,100
Market Cap $47.1M
Description
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.